Amikacin therapy for serious gram-negative infection
- 7 February 1977
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 237 (6) , 562-564
- https://doi.org/10.1001/jama.237.6.562
Abstract
Amikacin sulfate was administered to 18 patients for the treatment of 19 severe infections. Seventeen infections were caused by gentamicin-resistant Gram-negative bacilli, and 13 patients were bacteremic. Bacteriologic cure was attained in all but one instance, and effective serum, bile, and pleural fluid drug levels were demonstrated. Drug-related fever occurred in one patient, and another experienced a maculopapular rash and monilial intertrigo. In three patients, reversible renal toxicity developed, but none had clinical evidence of ototoxicity. Amikacin sulfate in a dose of 15 mg/kg/day is an effective antibiotic for the treatment of serious Gram-negative infections, particularly those due to gentamicin-resistant organisms. (JAMA237:562-564, 1977)This publication has 3 references indexed in Scilit:
- Amikacin Therapy for Serious Gram-Negative Bacillary InfectionsAnnals of Internal Medicine, 1975
- Amikacin Therapy for Severe Gram-Negative SepsisAnnals of Internal Medicine, 1975
- ANTIBIOTIC SUSCEPTIBILITY TESTING BY A STANDARDIZED SINGLE DISK METHOD1966